p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma

Gynecologic Oncology

Volumn 77, Issue 3, 2000, Pages 439-445

  Schmitz, Mary Jo ^a   Hendricks, Denver T ^b   Farley, John ^a   Taylor, Robert R ^a   Geradts, Joseph ^c   Rose, G Scott ^a   Birrer, Michael J ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cyclin D1; Endometrial cancer; K ras; p16; p27; p53; Rb; Uterine papillary serous carcinoma

Indexed keywords

CYCLIN D1; PROTEIN P16; PROTEIN P27; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN;

ARTICLE; CLINICAL ARTICLE; ENDOMETRIOID CARCINOMA; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; ONCOGENE K RAS; OVARY CARCINOMA; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; UTERUS CARCINOMA;

EID: 0034123121     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2000.5814     Document Type: Article

References (41)

1. Landis S H, Murray T, Bolden S, Wingo P A. Cancer statistics, 1998. CA Cancer J Clin. 48:1998;6-30.
2. Wilson T O, Podratz K C, Gaffey T A, Malkasian G D Jr, O'Brien P C, Naessens J M. Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. Am J Obstet Gynecol. 162:1990;418-423.
3. Lloyd R V, Erickson L A, Jin L, Kulig E, Qian X, Cheville J C, Scheithauer B W. p27kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol. 154:1999;313-323.
4. Arnold A, Kim H G, Gaz R D, Eddy R L, Fukusima Y, Kronenberg H M. Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest. 83:1989;2034-2040.
5. Worsley S D, Ponder B AJ, Davis R R. Overexpression of cyclin D1 in epithelial ovarian tumors. Gynecol Oncol. 64:1997;189-195.
6. Anayama T, Furihata M, Ishikawa T, Ohtsuki Y, Ogoshi S. Positive correlation between p27Kip1 expression and progression of human esophageal squamous cell carcinoma. Int J Cancer. 79:1998;439-443.
7. Kornmann M, Ishiwata T, Itakura J, Tangvoranuntakul P, Beger H G, Korc M. Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival. Oncology. 55:1998;363-369.
8. Michalides R F, Hageman P, van Tinteren H, Houben L, Weintjens E, Klompmaker P, Pterse J. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer. 73:1996;728-734.
9. Wang T C, Cardiff R D, Zukerberg L, Lees E, Arnold A, Schmidt E V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 369:1994;669-671.
10. Teneriello M G, Ebina M, Linnoila R I, Henry M, Nash J D, Park R C, Birrer M J. p53 and ki-ras gene mutations in epithelial ovarian neoplasm. Cancer Res. 53:1993;3103-3108.
11. Castavelos C, Bhattacharya N, Ung Y, Wilson J, Roncari L, Sandhu C. Decreased levels of the cell-cycle inhibitor p27kip1 protein: Prognostic implications in primary breast cancer. Nat Med. 3:1997;227-230.
12. Taylor R R, Linnoila R I, Gerardts J, Teneriello M G, Nash J D, Park R C, Birrer M J. Abnormal expression of the retinoblastoma gene in ovarian neoplasma and correlation to p53 and K-ras mutations. Gynecol Oncol. 58:1995;307-311.
13. Geradts J, Kratzke R A, Niehans G A, Lincoln C E. Immunohistochemical detection of cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1(CDKN2/MTS1) product p16ink4a in archival human solid tumors: Correlation with retinoblastoma protein expression. Cancer Res. 55:1995;6006-6011.
14. Kawamata N, Morosetti R, Miller C W. Molecular analysis of the cyclin dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res. 55:1995;2266-2269.
15. Barakat R R, Park R C, Grigsby P W, Muss H D, Norris H J. Corpus: Epithelial tumors. Hoskins W J, Perez C A, Young R C. Principles and Practice of Gynecologic Oncology. 1997;Lippincott-Raven, Philadelphia.
16. Caduff R F, Svoboda-Newman S M, Bartos R E, Ferguson A W, Frank T S. Comparative analysis of histologic homologues of endometrial and ovarian carcinoma. Am J Surg Pathol. 22:1998;319-326.
17. Bamberger A, Riethdorf L, Milde-Langosch K, Bamberger C M, Thuneke I, Erdmann I, Schulte H M, Löning T. Strongly reduced expression of the cell cycle inhibitor p27 in endometrial neoplasia. Virchow's Arch. 434:1999;423-428.
18. Masciullo V, Sgambato A, Pacilio C, Pucci B, Ferrandina G, Palazzo J, Carbone A, Cittadina A, Mancuso S, Scambia G, Giordano A. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res. 59:1999;3790-3794.
19. Sui L, Tokuda M, Ohno M, Hatase O, Hando T. The concurrent expression of p27 (kip1) and cyclin D1 in epithelial ovarian tumors. Gynecol Oncol. 73:1999;202-209.
20. Nikaido T, Li S F, Shiozawa T, Fujii S. Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas. Cancer. 78:1996;1248-1253.
21. Ito K, Sasano H, Yoshida Y, Sato S, Yajima A. Immunohistochemical study of cyclins D and E and cyclin dependent kinase (cdk) 2 and 4 in human endometrial carcinoma. Anticancer Res. 18:1998;1661-1664.
22. Shigemasa K, Tanimoto H, Parham G P, Parmley T H, Ohama K, O'Brien T J. Cyclin D1 overexpression and p53 mutation status in epithelial ovarian cancer. J Soc Gynecol Invest. 6:1999;102-108.
23. Hung W, Chai C, Huang J, Chuang L. Expression of cyclin D1 and c-Ki-ras gene product in human epithelial ovarian tumors. Hum Pathol. 27:1996;1324-1328.
24. Bancher-Todesca D, Gitsch G, Williams K E, Kohlberger P, Neunteufel W, Obermair A, Heinze G, Breitenecker G, Hacker N F. p53 protein overexpression: A strong prognostic factor in uterine papillary serous carcinoma. Gynecol Oncol. 71:1998;59-63.
25. Zheng W, Cao P, Zheng M, Kramer E E, Godwin T A. p53 overexpression and bcl-2 persistence in endometrial carcinoma: Comparison of papillary serous and endometrioid subtypes. Gynecol Oncol. 61:1996;167-174.
26. Kovalev S, Marchenko N D, Gugliotta B G, Chalas E, Chumas J, Moll U M. Loss of p53 function in uterine papillary serous carcinoma. Hum Pathol. 29:1998;613-619.
27. Moll U M, Chalas E, Auguste M, Meaney D, Chumas J. Uterine papillary serous carcinoma evolves via a p53-driven pathway. Hum Pathol. 27:1996;1295-1300.
28. Geisler J P, Geisler H E, Wiemann M C, Zhou Z, Miller G A, Crabtree W. p53 expression as a prognostic indicator of 5-year survival in endometrial cancer. Gynecol Oncol. 74:1999;468-471.
29. Shiozawa T, Xin L, Nikaido T, Fujii S. Immunohistochemical detection of cyclin A with reference to p53 expression in endometrial endometrioid carcinomas. Int J Gynecol Pathol. 16:1997;348-353.
30. Eltabbakh G H, Belinson J L, Kennedy A W, Biscotti C V, Casey G, Tubbs R R, Blumenson L E. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer. 80:1997;892-898.
31. Wen W H, Reles A, Runnebaum I B, Sullivan-Halley J, Bernstein L, Jones L A, Felix J C, Kreienberg R, El-Naggar A, Press M F. p53 and expression in ovarian cancers: Correlation with overall survival. Int J Gynecol Pathol. 18:1999;29-41.
32. Dong Y, Walsh M D, McGuckin M A, Cummings M C, Gabrielli B G, Wright G R, Hurst T, Khoo S K, Parsons P G. Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int J Cancer. 74:1997;407-415.
33. Sasaki H, Nishii H, Takahashi H, Tada A, Furusato M, Terashima Y, Siegal G P, Parker S L, Kohler M F, Berchuk A, Boyd J. Mutation of the Ki-Ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res. 53:1993;1906-1910.
34. Mandai M, Konishi I, Kuroda H, Komatsu T, Yamamoto S, Nanbu K, Matshushita K, Fukumoto M, Yamabe H, Mori T. Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology. Hum Pathol. 28:1998;34-40.
35. Nakashima R, Fujita M, Enomoto T, Haba T, Yoshino K, Wada H, Kurachi H, Sasaki M, Wakasa K, Inoue M, Buzard G, Murata Y. Br J Cancer. 80:1999;458-467.
36. INK4 in human endometrioid-type endometrial carcinoma. Cancer. 80:1997;2250-2256.
37. Milde Langosch K, Riethdorf L, Bamberger A, Löning T. p16/MTS1 and pRB expression in endometrial carcinomas. Virchow's Arch. 434:1999;23-28.
38. Milde-Langosch K, Ocon E, Becker G, Loning T. p16/MTS1 inactivation in ovarian carcinomas: High frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. Int J Cancer. 79:1998;61-65.
39. Fujita M, Enomoto T, Haba T, Nakashima R, Sasaki M, Yoshino K, Wada H, Buzard G S, Matszaki N, Wakasa K, Murata Y. Alteration of p16 and p15 genes in common epithelial ovarian tumors. Int J Cancer. 74:1997;148-155.
40. Niemann T H, Yilmaz A G, McGaughy V R, Vaccarello L. Retinoblastoma protein expression in endometrial hyperplasia and carcinoma. Gynecol Oncol. 65:1997;232-236.
41. Dodson M K, Cliby W A, Xu H, DeLacey K A, Hu S, Keeney G L, Li J, Podratz K C, Jenkins R B, Benedict W F. Evidence of functional Rb protein in epithelial ovarian carcinomas despite loss of heterozygosity at the Rb locus. Cancer Res. 54:1994;610-613.